NEW YORK (360Dx) – Akers Biosciences reported this week that its first quarter revenues dropped 55 percent year over year, as lower yields in the process of extracting antigens for its flagship test product led to lower production levels and backorders. Akers develops rapid screening and testing products.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.